Diligence memo · auto-generated · as of July 2, 2026
Cognito Therapeutics Group, Inc.
Cognito Therapeutics Group, Inc. has raised $196M over 1 round; too few niche peers to rank its valuation yet.
Businessfiled
Cognito Therapeutics Group, Inc. operates in Pharma, based in CAMBRIDGE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cognito Therapeutics Group, Inc. has raised $196M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $196M on 2025-03-19.
Most recent recorded round closed around 2025-03-19.
Valuation (modeled)modeled
Provath models Cognito Therapeutics Group, Inc. at approximately $1.7B (range $934M–$2.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Last raise 15 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 96% of Pharma peers (310 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Star Therapeutics LLC, Affinia Therapeutics Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.